VIP
RPRX icon

Viewpoint Investment Partners’s Royalty Pharma RPRX Stock Holding History

Viewpoint Investment Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,500
Closed -$328K – 105
2025
Q4 		$328K Buy
+8,500
New +$324K 0.16% 39

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viewpoint Investment Partners's RPRX Position: Q1 2026 in Review

Viewpoint Investment Partners sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 8,500 shares — an estimated $328K sold.

Viewpoint Investment Partners first reported a position in RPRX in Q4 2025 and held it in 1 quarter. The position peaked at $328K in Q4 2025. 592 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Viewpoint Investment Partners reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Viewpoint Investment Partners sold 8,500 Royalty Pharma shares in Q1 2026, an estimated $328K.
  • Viewpoint Investment Partners first reported a position in Royalty Pharma in Q4 2025 and held it in 1 quarter.
  • Viewpoint Investment Partners's Royalty Pharma position peaked at $328K in Q4 2025.
  • 592 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Viewpoint Investment Partners's 13F filing for Q1 2026, filed 23 Apr 2026.